CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
CIViC Variants/G12C

G12C

CIViC ID: 78 · Gene: KRAS

Variant Summary

Also known as
GLY12CYS,RS121913530
HGVS
NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T
Variant Type(s)
missense_variant
Evidence Items
18

Evidence Level Distribution

Level A: 3Level B: 7Level C: 1Level D: 7

Evidence Items

Showing CIViC evidence rows where gene = KRAS and variant = G12C.

LevelTypeDirectionSignificanceDiseaseDrugsRating
APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSotorasib5
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDivarasib4
APredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,Adagrasib4
APredictiveSupportsSensitivity/ResponseColorectal CancerPanitumumab,Sotorasib4
DPredictiveSupportsSensitivity/ResponseCancerEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-8533
BPredictiveSupportsResistanceColorectal CancerErlotinib,Gefitinib3
BPrognosticSupportsPoor OutcomeLung Non-small Cell Carcinoma3
CPredictiveSupportsResistanceColorectal CancerPanitumumab3
BPredictiveSupportsResistanceColorectal CancerChemotherapy,Cetuximab3
DPredictiveSupportsSensitivity/ResponseSolid TumorAdagrasib3
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDocetaxel,Selumetinib2
DPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,Dactolisib2
BPredictiveSupportsResistanceLung CancerGefitinib2
DPredictiveSupportsResistanceMultiple MyelomaMelphalan2
DPredictiveSupportsResistanceMultiple MyelomaMelphalan2
BDiagnosticSupportsPositiveLung Cancer2
DPredictiveSupportsResistanceColorectal CancerRegorafenib Anhydrous2
DPredictiveSupportsResistanceMultiple MyelomaMelphalan0